STATCenter·
STAT+: FDA approves Protagonist and Takeda’s drug for rare blood cancer
Mimrylo, from Takeda and Protagonist, is a new kind of treatment for the blood cancer polycythemia vera.
Read at STAT →
Health · 1 sources covering this
STAT+: FDA approves Protagonist and Takeda’s drug for rare blood cancer
Mimrylo, from Takeda and Protagonist, is a new kind of treatment for the blood cancer polycythemia vera.
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/02d520f4398b584bea35cfa5051f4138faa2f852" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="STAT+: FDA approves Protagonist and Takeda’s drug for rare blood cancer"></iframe>
